Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP4 | P49662 | 1/20 | 0.50 |
| ▸ | CASP5 | P51878 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16826407 | 0.92 | SIGMAR1 (0.58) | SIGMAR1 | |
| SCHEMBL16826410 | 0.86 | GAA (0.62) | HTR1ADRD4SIGMAR1CASP1CASP5 | |
| SCHEMBL16826398 | 0.83 | LTA4H (0.50) | HTR1ADRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL16825744 | 0.80 | CHIT1 (0.51) | HTR1ADRD2DRD3SIGMAR1 | |
| SCHEMBL16826405 | 0.79 | DRD2 (0.59) | HTR1ADRD2DRD3SIGMAR1 | |
| SCHEMBL16825679 | 0.78 | HTR1A (0.54) | HTR1ADRD2DRD3SIGMAR1 | |
| SCHEMBL11205135 | 0.78 | HTR1A (0.55) | HTR1ADRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL16825846 | 0.75 | CHIA (0.69) | SIGMAR1SLC6A3 | |
| SCHEMBL16826297 | 0.74 | LMNA (0.58) | HTR1AMAPT | |
| SCHEMBL14407778 | 0.74 | SLC6A3 (0.83) | HTR1ADRD2SIGMAR1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106659715-A | substituted aminotriazoles and methods of use thereof | 药物发现研究所 | 2017-05-10 | — | — | CN | claimed |
| EP-3082805-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | The Institute For Drug Delivery (US) | 2016-10-26 | — | — | EP | claimed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | claimed |
| WO-2015095701-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | THE INSTITUTE FOR DRUG DELIVERY (US) | 2015-06-25 | — | — | WO | claimed |
| EP-3082805-B1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INST FOR DRUG DISCOVERY LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-106659715-A | substituted aminotriazoles and methods of use thereof | 药物发现研究所 | 2017-05-10 | — | — | CN | disclosed |
| EP-3082805-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | The Institute For Drug Delivery (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2015095701-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | THE INSTITUTE FOR DRUG DELIVERY (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | CMA1, CHIA, AADAC | HTR1A 1948/4885DRD2 4668/4885DRD4 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.